Neurological complications of cancer immunotherapy (CAR T cells)

J Neurol Sci. 2021 May 15:424:117405. doi: 10.1016/j.jns.2021.117405. Epub 2021 Mar 18.

Abstract

Chimeric antigen receptor (CAR) T cell therapy has become an indispensable tool in the treatment of advanced malignancy, however, it is associated with significant neurologic toxicity. The pathophysiology of CAR T-cell associated neurotoxicity is incompletely understood, and the specific risk factors have only recently begun to be characterized. Despite a growing clinical experience with CAR T cell therapy, the unpredictability of neurologic symptoms remains a source of great anxiety for patients and practitioners alike, and a major limitation for more widespread adoption of this important treatment modality. The purpose of this review is to familiarize clinicians with the typical clinical manifestations and salient features of CAR T cell associated neurotoxicity. We place an emphasis on highlighting the clinical and laboratory markers that may be helpful for predicting clinical course, allowing teams to anticipate necessary supportive measures. We will also review the appropriate diagnostic workup for CAR T cell neurotoxicity and current treatment recommendations.

Keywords: CAR T cells; Neuro-oncology; Neuroimmunology.

Publication types

  • Review

MeSH terms

  • Humans
  • Immunotherapy / adverse effects
  • Immunotherapy, Adoptive
  • Neoplasms* / complications
  • Neoplasms* / therapy
  • Receptors, Chimeric Antigen*
  • T-Lymphocytes

Substances

  • Receptors, Chimeric Antigen